- Home
- CTO vs ABVX Comparison
CTO vs ABVX Comparison
Compare CTO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- ABVX
- Stock Information
- Founded
- CTO 1902
- ABVX 2013
- Country
- CTO United States
- ABVX France
- Employees
- CTO N/A
- ABVX N/A
- Industry
- CTO Real Estate Investment Trusts
- ABVX
- Sector
- CTO Real Estate
- ABVX
- Exchange
- CTO Nasdaq
- ABVX Nasdaq
- Market Cap
- CTO 615.7M
- ABVX 722.3M
- IPO Year
- CTO N/A
- ABVX N/A
- Fundamental
- Price
- CTO $19.53
- ABVX $9.50
- Analyst Decision
- CTO Strong Buy
- ABVX Strong Buy
- Analyst Count
- CTO 4
- ABVX 6
- Target Price
- CTO $21.50
- ABVX $36.50
- AVG Volume (30 Days)
- CTO 457.2K
- ABVX 82.3K
- Earning Date
- CTO 10-24-2024
- ABVX 09-09-2024
- Dividend Yield
- CTO 7.78%
- ABVX N/A
- EPS Growth
- CTO N/A
- ABVX N/A
- EPS
- CTO 0.61
- ABVX N/A
- Revenue
- CTO $118,662,000.00
- ABVX $9,676,417.00
- Revenue This Year
- CTO N/A
- ABVX $31.67
- Revenue Next Year
- CTO $13.12
- ABVX $1,189.66
- P/E Ratio
- CTO $32.24
- ABVX N/A
- Revenue Growth
- CTO 16.61
- ABVX 100.87
- 52 Week Low
- CTO $16.16
- ABVX $8.75
- 52 Week High
- CTO $21.15
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- CTO 48.13
- ABVX 34.50
- Support Level
- CTO $19.48
- ABVX $10.27
- Resistance Level
- CTO $20.87
- ABVX $10.79
- Average True Range (ATR)
- CTO 0.43
- ABVX 0.36
- MACD
- CTO -0.05
- ABVX -0.05
- Stochastic Oscillator
- CTO 24.72
- ABVX 8.16
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.